FIELD: medicine, pharmaceutics.
SUBSTANCE: present group of inventions refers to a method for producing GLU-EGFRvIII conjugate containing a combination of glutamic acid and a linker and enabling glutamic acid and the linker to react throughout the period of time ranging from 30 to 60 minutes; providing a peptide containing SEQ ID NO:1, to an activated product of glutamic acid prepared at the previous stage to produce the GLU-EGFRvIII conjugate; the linker:glutamic acid ratio falls within the range of 75:1 to 325:1, as well as to the GLU-EGFRvIII conjugate produced by the presented method.
EFFECT: group of inventions discloses the effective methods for producing and processes of a therapeutic agent.
7 cl, 26 dwg, 8 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SYNTHETIC PEPTIDE FOR PREPARING MONOSPECIFIC ANTIBODIES AGAINST ISOFORM 2 OF EUKARYOTIC TRANSLATION ELONGATION FACTOR 1A | 2013 |
|
RU2562880C2 |
| LIQUID COMPOSITION OF LONG-ACTING INSULIN AND INSULINOTROPIC PEPTIDE | 2013 |
|
RU2643766C2 |
| PRODRUGS CONTAINING HYALURONIC ACID CONJUGATE, LINKER AND DOUBLE AGONIST GLP-1/GLUCAGON | 2016 |
|
RU2719482C2 |
| EXENATIDE ANALOGUE CONJUGATES WITH DELAYED RELEASE | 2017 |
|
RU2764547C2 |
| LIPOSOMES CONTAINING CELL PENETRATING PEPTIDES AND TETRAESTER LIPIDS FOR ORAL DELIVERY OF MACROMOLECULES | 2016 |
|
RU2743431C2 |
| LIQUID FORMULATION OF LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE | 2013 |
|
RU2671576C2 |
| METHOD OF TREATING OR PREVENTING DISEASE ASSOCIATED WITH DEPOSIT OF AMYLOID PROTEINS (VERSIONS) | 2010 |
|
RU2533806C2 |
| GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | 2007 |
|
RU2460543C2 |
| VACCINE COMPOSITION AND USE THEREOF | 2016 |
|
RU2726411C2 |
| PEPTIDE REPRESENTING ANALOG OF ALPHA-FETOPROTEIN FRAGMENT, CONJUGATE OF PEPTIDE WITH DOXORUBICIN AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF FOR TREATMENT OF ONCOLOGY DISEASE | 2006 |
|
RU2317102C1 |
